Great Basin Corporation, a Salt Lake City, UT-based molecular diagnostics company developing sample-to-result solutions, has raised $9.5m in Series B funding.
The round is led by unnamed returning private investors.
Led by Ryan Ashton, president and CEO, Great Basin Corporation commercializes innovative chip-based technologies designed to provide fast and multiple-pathogen diagnoses of infectious diseases. .
The company intends to use the funds to expand manufacturing, fund research and development —including product menu expansion and the development of its Portrait Analyzer – and to increase its global commercialization efforts. Great Basin received clearance from the U.S. Food and Drug Administration (FDA) for its first product, a molecular diagnostic test for toxigenic Clostridium difficile (C. diff) at the beginning of May, and launched sales of the platform in November 2012.